Initial clinical data from the Phase 1 OUTRACE program for CLN-978 in treatment-refractory rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) was released. As of January 14, 2026, 14 patients were dosed across RA (n=5) and SLE (n=9) cohorts. 9 out of 11 patients showed B cell depletion >75% following 10 mcg dosing. 4 out of 5 RA patients showed decreases in DAS28-ESR scores, with 1 patient achieving remission. 5 out of 6 SLE patients showed a decrease in SLEDAI scores of >4 points. CLN-978 was reported as well-tolerated with a favorable safety profile.